Journal
ANTICANCER RESEARCH
Volume 39, Issue 11, Pages 5879-5890Publisher
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.13792
Keywords
Breast cancer; steroid receptor; mineralocorticoid receptor; immunohistochemistry; prognosis
Categories
Ask authors/readers for more resources
Background/Aim: The aim of the study was to investigate the prognostic role of androgen receptor (AR), mineralocorticoid receptor (MR) and glucocorticoid receptor beta (GR beta) expression in HER-2 negative breast cancer patients. Materials and Methods: The study population (n=152) was enriched with triple-negative breast cancers (TNBC) (n=96; 63.2%). The median follow-up time was 100 months. AR, MR and GR beta immunocytochemical staining was compared with that of epithelial-mesenchymal transition (EMT) markers (vimentin, SIP1, ZEB1). Results: High expression of cytoplasmic MR was associated with dismal local relapse-free survival (RR=13.923; 95%CI=1.071-181.045; p=0.044) in tumours with non-TNBC phenotype. AR and GR beta were more frequently expressed in ER+/PR+/HER2-tumours, while cytoplasmic MR was more often expressed in TNBC tumours (for all, p<0.0005). GR beta and AR were associated with decreased vimentin expression (p<0.005), indicating their association with attenuated EMT. Conclusion: Cytoplasmic MR expression is a strong predictor of local recurrence in non-metastatic breast cancer patients with non-TNBC tumour phenotype.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available